How Should Practitioners Evaluate Scar Risk Prior To Performing Invasive Thermal Treatments Or Laser Resurfacing, And What Post-Care Strategies Prevent Abnormal Scarring? Key Steps For Safe Practice

Evaluate scar risk before treating, then control inflammation early. Before invasive thermal treatments or laser resurfacing, practitioners should perform a full-body skin examination, document existing scars, and obtain a personal and family history of keloids or hypertrophic scars. Higher-risk ancestry, previous abnormal scarring, active infection or inflammation, and treatment in delicate anatomical areas should prompt a more conservative plan or deferral. After treatment, careful wound care, sun protection, silicone therapy after re-epithelialization, and rapid clinical review of persistent erythema or induration can reduce the likelihood of abnormal scarring.

The safest protocol is risk-adapted treatment: identify patients and tissue conditions that may heal poorly, limit unnecessary thermal injury, and intervene promptly when inflammation does not follow the expected recovery pattern.

How to Identify Scar Risk Before Treatment

Examine the Entire Skin Surface

A full-body examination can reveal prior hypertrophic scars or keloids that the patient may not mention or may not recognize as clinically important.

Assess scars for height, thickness, firmness, pliability, texture, erythema, pigmentation, and vascularity. Measurements such as diagnostic ultrasound or a structured scar scale can improve baseline documentation when a scar is already present.

Take a Personal and Family Scar History

Ask specifically whether previous injuries, piercings, surgeries, burns, injections, or cosmetic procedures produced scars that became raised, firm, itchy, painful, or larger than the original wound.

A family history of keloids or hypertrophic scars is important because abnormal scar behavior can occur even when the patient has not undergone many prior procedures.

Consider Ancestry and Skin Phototype

Keloid and hypertrophic scar formation occurs more frequently in people of African, Asian, and Hispanic ancestry, as well as in some Caucasian populations. Ancestry is a risk marker, not a diagnosis, and should be considered alongside the patient’s actual scar history and examination.

Skin phototype also affects treatment planning. Higher phototypes have greater risk of post-inflammatory hyperpigmentation, while prior scar treatment may have changed the tissue’s response to heat and injury.

Screen for Medical and Treatment Factors

Ask about recent isotretinoin exposure, prior radiation therapy, impaired wound healing, immune compromise, and medications or conditions that could affect recovery.

Active skin infection is a reason to defer treatment because thermal injury can worsen tissue damage and potentially facilitate spread. Active inflammatory dermatoses should also be controlled before treatment because inflammation can interfere with healing and collagen remodeling.

How Risk Should Change the Treatment Plan

Defer Aggressive Treatment When Necessary

A strong personal or family history of abnormal scarring does not automatically prohibit every procedure, but it may make aggressive ablative resurfacing or high-energy microneedling RF inappropriate.

When the expected benefit does not justify the scar risk, defer treatment, treat the underlying skin condition, or choose a less invasive alternative.

Use Staged and Conservative Treatment

For higher-risk patients, consider milder, staged, non-ablative treatments or lower thermal energy settings rather than attempting the maximum effect in one session.

Test spots with different fluences and pulse durations can help establish a safer working threshold before treating the full area. Results should be assessed over time before increasing treatment intensity.

Adjust for Anatomical Vulnerability

The mandible, anterior neck, and infraorbital regions can be more vulnerable to thermal injury or difficult healing. Use reduced energy settings and avoid unnecessary overlap in these areas.

The treatment plan should account for local skin thickness, vascularity, mobility, and the patient’s history of healing in that region.

Prevent Excessive Thermal Injury

The main procedural cause of abnormal scarring is excessive dermal thermal injury. Risk increases with high fluence, inadequate cooling, pulse stacking, and multiple overlapping passes.

Use reliable contact or air cooling, follow validated parameter protocols, and avoid repeated passes over the same tissue unless the device-specific protocol clearly supports them.

Monitor Tissue During Treatment

Marked erythema, epidermal graying, or other signs of overtreatment should be treated as warning signals. The operator should reduce the parameters, stop overlapping passes, or pause treatment and reassess the tissue.

A visible endpoint is not permission to continue escalating energy. Tissue response should govern the procedure.

Post-Care Strategies That Reduce Abnormal Scarring

Protect the Wound During Re-Epithelialization

Follow the device- and procedure-specific wound-care protocol, including appropriate cleansing, moisture control, and protection from friction or contamination.

For procedures that create an open wound, semi-occlusive or occlusive dressings may support re-epithelialization when clinically appropriate. Dressings should be selected and monitored by the treating clinician, particularly if infection is a concern.

Control Excessive Inflammation Promptly

Persistent or worsening erythema, pruritus, induration, pain, or thickening is not equivalent to routine post-procedure redness. These findings require early assessment for infection, delayed healing, contact reaction, or emerging hypertrophic scarring.

When abnormal inflammation or induration is identified, clinicians may use topical or intralesional corticosteroids to suppress inflammatory signaling and excessive collagen production. Steroid potency, timing, and route must be individualized because excessive steroid exposure can impair healing, thin skin, or mask infection.

Begin Silicone After the Surface Has Healed

Once re-epithelialization is complete, commonly around two weeks but dependent on the procedure and patient, topical silicone gel or silicone sheeting can support scar remodeling.

Silicone is most useful when applied consistently over the following weeks to months. It should not be placed over an open, draining, or infected wound unless specifically directed by the treating clinician.

Use Strict Photoprotection

Sun exposure can intensify erythema and post-inflammatory hyperpigmentation, especially in darker phototypes. Use broad-spectrum sunscreen, physical protection, and practical sun avoidance during recovery.

Pre-treatment pigment management may be appropriate for selected patients, but agents such as hydroquinone, tretinoin, glycolic acid, and vitamin C should be prescribed and timed around the procedure to avoid irritating a healing skin barrier.

Escalate When a Scar Is Evolving

A scar that becomes progressively raised, firm, itchy, painful, or extends beyond the original treatment area needs early specialist review. Early treatment is generally more useful than waiting for the scar to mature.

Options such as intralesional corticosteroids, silicone, and other scar-directed therapies should be selected according to the scar’s morphology and the condition of the healed skin. Imiquimod and other immune-modulating treatments are not routine substitutes for assessment and should be considered only in carefully selected, clinician-directed circumstances.

Understanding the Trade-Offs

More Energy Does Not Guarantee Better Results

Increasing fluence, stacking pulses, or adding passes may improve treatment intensity but also increases the risk of prolonged inflammation, delayed healing, pigmentary change, and abnormal scarring.

A staged course often provides a better risk-benefit balance than pursuing the maximum endpoint in one session.

Steroids Require Careful Judgment

Corticosteroids can reduce fibroblast activity and excessive collagen synthesis when abnormal inflammation is emerging. However, inappropriate use can delay wound healing, worsen infection risk, or cause local skin atrophy.

They should be used for a defined clinical indication and monitored rather than applied automatically to every patient.

Pigment Risk and Scar Risk Are Different

A patient may have a low tendency toward hypertrophic scarring but a high risk of post-inflammatory hyperpigmentation. Conversely, someone with a history of keloids may have relatively little pigment change but substantial structural scar risk.

Consent and treatment planning should address both risks separately.

Early Redness Can Be Normal

Expected erythema after resurfacing does not by itself prove that a hypertrophic scar is forming. The concerning pattern is persistent or worsening erythema accompanied by induration, pruritus, progressive elevation, pain, or delayed re-epithelialization.

Clinical follow-up is therefore part of prevention, not merely a response to a complication.

How to Apply This to Your Procedure

The final protocol should be individualized to the patient, device, anatomical site, and expected depth of injury.

If your primary focus is identifying high-risk patients: Perform a full-body scar examination and document personal and family histories of keloids or hypertrophic scars before selecting treatment intensity.
If your primary focus is reducing procedural injury: Use test spots, adequate cooling, conservative energy settings, and no unnecessary overlapping passes, particularly on vulnerable anatomical regions.
If your primary focus is preventing abnormal scar maturation: Monitor closely for persistent erythema, itching, induration, or elevation and arrange prompt clinician-directed anti-inflammatory treatment when these signs appear.
If your primary focus is supporting normal remodeling: Begin silicone gel or sheeting only after complete re-epithelialization and maintain consistent photoprotection throughout recovery.
If your primary focus is treating patients with substantial risk: Consider deferral, staged non-ablative treatment, or referral to a practitioner experienced in managing high-risk scar biology.

The core principle is simple: match treatment intensity to the patient’s healing risk and intervene before abnormal inflammation becomes a mature scar.

Summary Table:

Risk Factor	Assessment Method	Impact on Treatment Plan	Post-Care Strategy
Personal/family history of keloids	Detailed history, full-body exam	Conservative or deferred treatment	Early silicone therapy, close monitoring
Ancestry (African, Asian, Hispanic)	Patient interview	Consider lower energy settings	Strict photoprotection, monitor for hyperpigmentation
Skin phototype	Fitzpatrick scale	Adjust energy and cooling	Sun protection, pigment management
Active infection/inflammation	Clinical examination	Defer treatment until resolved	Treat infection first, then proceed
Anatomical location (e.g., neck, mandible)	Knowledge of high-risk areas	Reduce energy, avoid overlap	Silicone after healing, early intervention if induration
Procedure parameters (fluence, stacking)	Review treatment protocol	Use conservative settings, test spots	Avoid excessive thermal injury, monitor tissue response

Ensure your patients' safety and achieve optimal outcomes with BELIS's advanced aesthetic devices. Our portfolio includes cutting-edge laser systems, IPL, and more, designed for precise control and minimal risk. Learn how our technology can help you implement risk-adapted protocols and enhance patient satisfaction. Contact us today to discuss your needs.